SCHEMBL6695836

SCHEMBL6695836

Cc1nc[nH]c1CN1c2ccccc2CC(Cc2ccc(C(C)(C)C)cc2)C(=O)N1C(C)c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.37
DRD2 P14416 2/20 0.33
DRD4 P21917 1/20 0.33
GAA P10253 2/20 0.33
HTT P42858 2/20 0.33
NPSR1 Q6W5P4 1/20 0.33
GPR55 Q9Y2T6 1/20 0.33
HDAC6 Q9UBN7 1/20 0.32
MAPT P10636 1/20 0.32
KMT2A Q03164 3/20 0.32
NPC1 O15118 1/20 0.32
ALDH1A1 P00352 1/20 0.32
RAB9A P51151 1/20 0.32
MEN1 O00255 2/20 0.31
HTR2A P28223 1/20 0.30
HTR2C P28335 1/20 0.30
HTR2B P41595 1/20 0.30
SIGMAR1 Q99720 1/20 0.30
TSHR P16473 1/20 0.30
EDNRB P24530 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6695838 0.85 CYP2C9 (0.39) CYP2C9DRD2DRD4GAAHTT
SCHEMBL6694520 0.85 HTT (0.35) CYP2C9DRD2DRD4GAAHTT
SCHEMBL6694523 0.71 ALDH1A1 (0.35) CYP2C9DRD2DRD4GAAHTT
SCHEMBL6701645 0.71 EPHX1 (0.33) DRD2DRD4GAAHDAC6MAPT
SCHEMBL6701976 0.63 MTNR1A (0.36) CYP2C9DRD2
SCHEMBL7255157 0.62 MTNR1A (0.36)
SCHEMBL6701647 0.62 MAPK1 (0.39) GAAHDAC6MAPTKMT2ANPC1
SCHEMBL28995160 0.62 DRD2 (0.46) DRD2DRD4GAAMAPTKMT2A
SCHEMBL30489343 0.62 DRD2 (0.46) DRD2DRD4GAAMAPTKMT2A
SCHEMBL7255593 0.62 HDAC6 (0.34) CYP2C9HDAC6KMT2AALDH1A1SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040009972-A1 Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase BRISTOL-MYERS COMPANY 2004-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009972-A1 Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase MT-ATP6, MT-CO1, ATP5ME CYP2C9 229/4885DRD2 452/4885DRD4 642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.